~~<i id='5BD7984FC5'><strike id='5BD7984FC5'><tt id='5BD7984FC5'><pre id='5BD7984FC5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：explore 2025-09-05 11:25:47 - browse：86

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Why Marc Tessier

focus

knowledge

focus

hotspot

focus

SuzanneKreiter/GlobestaffCVSHealthisperhapsbestknownfortwothings.First,therearethecomicallylongrecei

WSS

Inaction leaves children at risk from dangerous chemotherapy drug

What is artificial intelligence? Experts weigh in

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Dana Farber says 6 studies to be retracted and 31 corrected

Dana Farber says 6 studies to be retracted and 31 corrected

Head of FDA's diagnostics center, who led through Covid, retires

knowledge

entertainment

focus

ChatGPT in medicine: STAT answers readers' burning questions

High breast density mammograms need follow

Virginia high school admissions case could be legal follow

FDA sets aggressive timeline for overhauling inspection procedures

In Memoriam: Notable people who died in 2023

Mass General, Mayo Clinic look to monetize custom

Psychedelics group wrestles with new pharma identity

Dog Aging Project founders on what lies ahead after losing funding

Cancer drug shortages should be causing more outrage

Listen: BridgeBio's big week & Lilly's Alzheimer's data

knowledge

A pediatrician calls for Congress to pass the child tax credit deal

A pediatrician calls for Congress to pass the child tax credit deal

Reframing the conversation around gain

Medicare bonuses could stop drug shortages under Senate plan

CVS is on a mission to consolidate health care. Will it work?

Dog Aging Project founders on what lies ahead after losing funding

focus

hotspot

focus

focus